6.80
+0.215(+3.27%)
Currency In USD
| Previous Close | 6.58 |
| Open | 6.71 |
| Day High | 6.99 |
| Day Low | 6.5 |
| 52-Week High | 22.33 |
| 52-Week Low | 5.77 |
| Volume | 74,380 |
| Average Volume | 387,809 |
| Market Cap | 224.68M |
| PE | -0.54 |
| EPS | -12.64 |
| Moving Average 50 Days | 7.61 |
| Moving Average 200 Days | 11.59 |
| Change | 0.22 |
If you invested $1000 in Lexeo Therapeutics, Inc. Common Stock (LXEO) since IPO date, it would be worth $676.12 as of January 02, 2025 at a share price of $6.795. Whereas If you bought $1000 worth of Lexeo Therapeutics, Inc. Common Stock (LXEO) shares 1 year ago, it would be worth $458.19 as of January 02, 2025 at a share price of $6.795.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
GlobeNewswire Inc.
Dec 19, 2024 12:00 PM GMT
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disea
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Oct 30, 2024 10:14 AM GMT
Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts